Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hovione | Contract Pharma

What are you searching for?

Sign in

Search by

Hovione

Company Headquarters

14 Lindenstrasse, Baar Switzerland, Baar, ZG, 6340, CH

Driving Directions Phone: View Phone Fax: View Fax
View website

Request more information from Hovione

Request more information from Hovione

Categories from Hovione

Accelerated Stability Studies
Agglomeration
Analytical Laboratory Services
Analytical Methods Development
Analytical Validation Studies
API Solubilization Technologies
Aseptic Processing
Assay Development
Bioavailability Studies
cGMP Synthesis
Chemical Analysis
Chemistry, Computational
Chiral Separations, R&D
Chromatographic Analysis, LC/GC
Chromatography
Clean Room Equipment and Supplies
Clinical Trials, Phase I
Clinical Trials, Phase II
CMC (Chemistry, Manfacturing & Controls)
Commercial Drug Sourcing
Contract Development and Manufacturing Organization (CDMO)
Contract Manufacturing
Contract Research
Custom Manufacturing
Custom Synthesis
Distillation
Dosage Form Development
Drug Delivery Systems
Drug Design
Drug Development Services
Drug Screening
Encapsulation
Feasibility Studies
Filling, Capsule
Filtration Services
Fluid Bed Processing
Formulation Development
Formulation Services
Formulation, Controlled Release
Granulation
High Throughput Screening
Hot Melt Extrusion
HPLC
Lyophilization
Manufacturing, API
Manufacturing, API, High Potency
Manufacturing, Clinical Trials Supply
Manufacturing, Controlled Substances
Manufacturing, Custom
Manufacturing, Cytotoxic & High Potency Compounds
Manufacturing, Generics
Manufacturing, High Containment Operations
Manufacturing, Inhalables
Manufacturing, Oral Drug Delivery
Methods Development
Methods Validation
Microencapsulation
Micronization
Organic Synthesis
Particle Characterization
Particle Size Analysis
Particle Size Classification
Preformulation
Process Analytical Technology (PAT)
Process Development/Scale-Up Services
Process R&D
Process Validation Studies
Project Management
QA/QC
R&D Services
Scale-Up
Size Reduction
Spray Drying
Stability Studies
Stability, ICH
Sterilization
Supplier, Fine Chemicals
Sustained Release Delivery Systems
Technology Transfer
X-Ray Powder Diffraction
Overcoming Solubility Challenges at Hovione’s Expanded NJ Site

VideoBites

Overcoming Solubility Challenges at Hovione’s Expanded NJ Site

David Basile of Hovione discusses expanded spray drying capacity in East Windsor and the benefits of integrated development, scale-up, and manufacturing at a single U.S. site.

Released By Hovione

Related Content

Videos

The Friday Brief for September 18, 2026: Companies Expand in US & Europe

Hovione, Upperton, Piramal Pharma, Syntegon, Evonik, and Fareva opened or announced plans to build new facilities.

By: Patrick Lavery

Marco Gil, co-CEO, Hovione; Janice Mironov, Mayor, East Windsor, NJ; Debbie Hart, President, BioNJ; Antonio Almeida, co-CEO, Hovione; David Basile, VP of TechOps - Americas, Hovione

Breaking News

Hovione Doubles US Spray-Drying Capacity With Opening of New NJ Facility

This closes a $100 million investment cycle, and creates approximately 80 new jobs.

By: Patrick Lavery

Promotions & Moves

Hovione Names Stefan Doboczky as CEO

Doboczky has served as Chairman of the Board of Directors of Hovione Holding AG since 2024.

By: Charlie Sternberg

Breaking News

Hovione Completes Expansion of Loures, Portugal Tablet Manufacturing Center

The expansion increases commercial-scale batch tableting capacity for integrated supply of oral solid dosage products by 25%.

By: Patrick Lavery

Online Exclusives

Hovione Planning Ribbon-Cutting at NJ Facility – A Behind-the-Scenes Preview

The company is building out more than 200,000 square feet of space in New Jersey.

By: Patrick Lavery

Promotions & Moves

Jean Luc Herbeaux Steps Down as CEO of Hovione

Two interim co-CEOs have been named as the Board searches for a successor.

By: Charlie Sternberg

Collaborations & Alliances

Hovione, IDC Launch Intranasal Drug Delivery Platform

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing.

By: Charlie Sternberg

Online Exclusives

Hovione Eyeing Manufacturing Expansion on Both Sides of Atlantic

The CDMO is preparing for its New Jersey facility to become fully operational this year.

By: Patrick Lavery

Features

CEO Spotlight: Hovione’s Jean-Luc Herbeaux

Hovione’s chief executive shares his vision for establishing and maintaining leadership as a CDMO.

By: Charlie Sternberg

Hovione

VideoBites

Overcoming Solubility Challenges at Hovione’s Expanded NJ Site

David Basile of Hovione discusses expanded spray drying capacity in East Windsor and the benefits of integrated development, scale-up, and manufacturing at a single U.S. site.

Released By Hovione

Breaking News

Hovione Invests $100M in New Jersey Manufacturing Site

The investment grows its U.S. operations and enhances its integrated drug substance, drug product intermediate, and drug product capabilities.

By: Charlie Sternberg

Collaborations & Alliances

Hovione, Microinnova Partner to Test Modular Manufacturing Equipment

Aim to accelerate drug development and production with new technologies.

By: Charlie Sternberg

Collaborations & Alliances

Hovione & Firstgene Partner on HCC Targeted Therapy

Aim to advance Hovione’s proprietary virus-like particle drug delivery platform for the targeted treatment of Hepatocellular Carcinoma.

By: Charlie Sternberg

Breaking News

Hovione Expands in Europe and U.S.

Increases its global spray drying capacity and enhances its capabilities.

Collaborations & Alliances

Hovione and iBET Launch New Joint Venture, ViSync Technologies

Aims to develop innovative solutions to address the unmet technical needs of pharmaceutical companies in the cell and gene therapy space.

By: Charlie Sternberg